Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines (This dataset does not contain this module)
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE189460

Dataset summary for GSE189460

Datast information	Dataset	GSE189460
	PMID	36380017
	Raw data ID/link	PRJNA783047
	Organism	Homo sapiens
	Source	patients
	Tissue	Bone marrow aspirate
	Cancer type level1	Multiple myeloma
	Cancer type level2	Multiple myeloma (MM)
	Regimen	bortezomib + melphalan + prednisolone
	Drug type	Targeted therapy
	Sample size	pre (resistant 5, sensitive 13)
	Cell number	110638
	Extract protocol	10x genomics
	Data processing	CellRanger 3.0.1
	Public date	Public on Sep 14, 2022
	Description	This dataset has 18 patients with pre-treatment samples.

Top

Drug summary for GSE189460

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Bortezomib"	DB00188	small molecule	PSMB5; PSMB1	P28074; P20618
"melphalan" is not included in the drug list.
"Prednisolone"	DB00860	small molecule	NR3C1	P04150

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

resistant vs. sensitive

Dot plot of significant ligand-receptor pairs in the resistant group	Dot plot of significant ligand-receptor pairs in the sensitive group

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
PHPT1	ENSG00000054148	0.500514	0.00e+00	0.00e+00	0.822	0.601	Malignant cells	pre
PRKDC	ENSG00000253729	0.500069	0.00e+00	0.00e+00	0.446	0.169	Malignant cells	pre
ARMCX3	ENSG00000102401	0.499584	0.00e+00	0.00e+00	0.58	0.313	Malignant cells	pre
CD47	ENSG00000196776	0.499542	0.00e+00	0.00e+00	0.575	0.4	Malignant cells	pre
SNRPD3	ENSG00000100028	0.49884	0.00e+00	0.00e+00	0.572	0.299	Malignant cells	pre
RPS27	ENSG00000177954	0.498214	0.00e+00	0.00e+00	0.995	0.997	Malignant cells	pre
DNAJC9	ENSG00000213551	0.497626	0.00e+00	0.00e+00	0.321	0.067	Malignant cells	pre
USP1	ENSG00000162607	0.497524	0.00e+00	0.00e+00	0.337	0.109	Malignant cells	pre
SLBP	ENSG00000163950	0.49402	0.00e+00	0.00e+00	0.322	0.12	Malignant cells	pre
HIST1H2BN	NA	0.493338	0.00e+00	0.00e+00	0.305	0.071	Malignant cells	pre
NDUFA4	ENSG00000189043	0.491894	0.00e+00	0.00e+00	0.928	0.921	Malignant cells	pre
TCEAL3	ENSG00000196507	0.491659	0.00e+00	0.00e+00	0.318	0.067	Malignant cells	pre
HIST1H2BJ	NA	0.491122	0.00e+00	0.00e+00	0.286	0.1	Malignant cells	pre
ARL4C	ENSG00000188042	0.490173	0.00e+00	0.00e+00	0.301	0.067	Malignant cells	pre
LSM3	ENSG00000170860	0.489669	0.00e+00	0.00e+00	0.65	0.407	Malignant cells	pre
SMCHD1	ENSG00000101596	0.489423	0.00e+00	0.00e+00	0.481	0.237	Malignant cells	pre
PHF19	ENSG00000119403	0.489021	0.00e+00	0.00e+00	0.292	0.053	Malignant cells	pre
JTB	ENSG00000143543	0.488262	0.00e+00	0.00e+00	0.862	0.803	Malignant cells	pre
LY6E	ENSG00000278032	0.488247	0.00e+00	0.00e+00	0.537	0.334	Malignant cells	pre
SF3B6	ENSG00000115128	0.486457	0.00e+00	0.00e+00	0.666	0.39	Malignant cells	pre
SRSF2	ENSG00000161547	0.484851	0.00e+00	0.00e+00	0.726	0.553	Malignant cells	pre
ATP6V1G1	ENSG00000136888	0.484824	0.00e+00	0.00e+00	0.89	0.819	Malignant cells	pre
AL133467.1	NA	0.481276	0.00e+00	0.00e+00	0.322	0.052	Malignant cells	pre
TRA2B	ENSG00000136527	0.48111	0.00e+00	0.00e+00	0.67	0.431	Malignant cells	pre
PLAC8	ENSG00000145287	0.4811	0.00e+00	0.00e+00	0.427	0.19	Malignant cells	pre
GOLGB1	ENSG00000173230	0.480681	0.00e+00	0.00e+00	0.616	0.397	Malignant cells	pre
GPSM3	ENSG00000233490	0.479869	0.00e+00	0.00e+00	0.537	0.271	Malignant cells	pre
HNRNPD	ENSG00000138668	0.478922	0.00e+00	0.00e+00	0.644	0.414	Malignant cells	pre
AL031777.3	NA	0.477031	0.00e+00	0.00e+00	0.273	0.089	Malignant cells	pre
GNAS	ENSG00000087460	0.476037	0.00e+00	0.00e+00	0.98	0.969	Malignant cells	pre
SLC3A2	ENSG00000168003	0.475935	0.00e+00	0.00e+00	0.65	0.464	Malignant cells	pre
CRYBG3	ENSG00000080200	0.475648	0.00e+00	0.00e+00	0.402	0.162	Malignant cells	pre
ACTR3	ENSG00000115091	0.475593	0.00e+00	0.00e+00	0.581	0.298	Malignant cells	pre
GGH	ENSG00000137563	0.475576	0.00e+00	0.00e+00	0.338	0.116	Malignant cells	pre
HSPA8	ENSG00000109971	0.474509	0.00e+00	0.00e+00	0.931	0.82	Malignant cells	pre
EIF1	ENSG00000173812	0.474313	0.00e+00	0.00e+00	1	0.998	Malignant cells	pre
SELENOH	ENSG00000211450	0.472971	0.00e+00	0.00e+00	0.737	0.549	Malignant cells	pre
SRSF9	ENSG00000111786	0.472004	0.00e+00	0.00e+00	0.793	0.578	Malignant cells	pre
ARF6	ENSG00000165527	0.471407	0.00e+00	0.00e+00	0.526	0.325	Malignant cells	pre
MRPL51	ENSG00000111639	0.469481	0.00e+00	0.00e+00	0.716	0.466	Malignant cells	pre
MCM7	ENSG00000166508	0.467972	0.00e+00	0.00e+00	0.322	0.086	Malignant cells	pre
HNRNPA1	ENSG00000135486	0.466254	0.00e+00	0.00e+00	0.868	0.799	Malignant cells	pre
VPS13A	ENSG00000197969	0.46552	0.00e+00	0.00e+00	0.353	0.136	Malignant cells	pre
UBE2T	ENSG00000077152	0.465327	0.00e+00	0.00e+00	0.27	0.049	Malignant cells	pre
CD55	ENSG00000196352	0.464539	0.00e+00	0.00e+00	0.571	0.317	Malignant cells	pre
PPP1R15B	ENSG00000158615	0.464204	0.00e+00	0.00e+00	0.495	0.232	Malignant cells	pre
SLC38A1	ENSG00000111371	0.463563	0.00e+00	0.00e+00	0.498	0.217	Malignant cells	pre
CDKN1A	ENSG00000124762	0.462233	0.00e+00	0.00e+00	0.545	0.273	Malignant cells	pre
CCNI	ENSG00000118816	0.461908	0.00e+00	0.00e+00	0.819	0.631	Malignant cells	pre
DDX24	ENSG00000273761	0.461825	0.00e+00	0.00e+00	0.6	0.305	Malignant cells	pre

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug-resistant mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	2.10e-17	1.10e-16	945	781	86	23467	Malignant cells	ADAM10,AREG,BCL2L11,BAX,BCL2,CDKN1A,CDKN1B,DNMT1,FBXW7,GSTP1,HMGB1,ID1,EIF4G1,IFI27,JUN,PKM,MCL1,MAP1LC3B,MYC,PARP1,PTEN,KRAS,RALBP1,RHOA,S100A4,STMN1,TP53INP1,TPD52,TYMS,YWHAZ,SLC25A5,ANXA1,HSPA5,BTG1,CASP8,CCND1,CDKN2A,HSPD1,CXCR4,DDIT3,DUSP1,DUSP2,EGR1,EZH2,EZR,FGFR1,FTL,FUS,GAPDH,NR3C1,GRB2,HMGB2,HNRNPU,HSPA8,EIF4A1,NFKBIA,ITGB1,TCF4,MAP4K3,MDM4,NSD2,NUCKS1,PABPC1,PDCD4,PRKDC,PTPN18,RAC1,RAP1B,RND3,HNRNPA1,SFPQ,SMC4,SMARCC1,SRSF2,TNFAIP3,TOP1,UCP2,WEE1,YBX1,GNAS,NPM1,BRD2,G3BP1,PMVK,QPRT,HSH2D
Aberration of the Drug's Therapeutic Target	1.50e-01	3.90e-01	945	90	6	23467	Malignant cells	BCL2,CDKN2A,EZH2,FGFR1,SF3B1,NPM1
Epigenetic Alteration of DNA, RNA or Protein	3.80e-01	6.30e-01	945	455	20	23467	Malignant cells	BCL2L11,BCL2,DNMT1,FBXW7,H2AFY,LMNA,TYMS,PMAIP1,ARID4B,CDKN2A,CXCR4,EZH2,GAPDH,PDCD4,SMC4,TIMP1,CYTOR,MALAT1,PPP1R15A,MX1
Drug Inactivation by Structure Modification	6.70e-01	7.80e-01	945	27	1	23467	Malignant cells	GSTP1
Irregularity in Drug Uptake and Drug Efflux	7.80e-01	7.80e-01	945	37	1	23467	Malignant cells	SLC3A2

Enrichment results for 1 known drug resistance mechanisms in TME cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Regulation by the Disease Microenvironment	3.50e-01	3.50e-01	54	186	1	23467	B cells	RHOB
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	40	186	0	23467	CD4+ T cells	NA
Regulation by the Disease Microenvironment	1.90e-01	1.90e-01	190	186	3	23467	CD8+ T cells	TGFB1,CXCR4,TSPYL2
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	47	186	0	23467	cDCs	NA
Regulation by the Disease Microenvironment	8.70e-01	8.70e-01	255	186	1	23467	Erythrocytes	EZH2
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	3	186	0	23467	Fibroblasts	NA
Regulation by the Disease Microenvironment	1.90e-02	1.90e-02	194	186	5	23467	Mono_Macro	VEGFA,CX3CR1,IL1B,RHOB,VIM
Regulation by the Disease Microenvironment	4.20e-01	4.20e-01	68	186	1	23467	NK cells	CXCR4
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	17	186	0	23467	pDCs	NA
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	22	186	0	23467	Progenitors	NA

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group of the pre-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	hdpi__TCEAL2	5.69	0.165	TCEAL2 (directAnnotation).	B cells
	transfac_pro__M01281	5.5	0.16	ILF2; NFATC2 (directAnnotation).	B cells
	transfac_pro__M03555	5.38	0.157	ILF2; NFATC2 (directAnnotation).	B cells
	transfac_pro__M06332	4.86	0.145	ZNF585A (directAnnotation).	B cells
	transfac_pro__M07284	4.84	0.144	ERG (directAnnotation).	B cells
	transfac_pro__M07608	4.77	0.143	ILF2; NFAT5; NFATC1; NFATC2; NFATC4 (directAnnotation).	B cells
	metacluster_5.2	4.75	0.142	ZNF564 (directAnnotation).	B cells
	transfac_pro__M07301	4.69	0.141	NFATC4 (directAnnotation).	B cells
	hdpi__SCAND2	4.55	0.137	SCAND2P (directAnnotation).	B cells
	transfac_pro__M05779	4.38	0.133	ZNF674 (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89

Motifs and TFs regulating down-regulated DEGs in resistant group of the pre-treatment samples

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETV2_RFX5_NACTTCCGGYNNNNGCAACSN_CAP_repr	5.24	0.22	ETV2; RFX5 (directAnnotation).	B cells
	transfac_public__M00237	4.81	0.205	AHR; ARNT (directAnnotation).	B cells
	jaspar__MA0033.2	4.44	0.192	FOXL1 (directAnnotation).	B cells
	taipale_tf_pairs__ELK1_TBX21_TNRCACCGGAAGNN_CAP_repr	4.2	0.183	ELK1; TBX21 (directAnnotation).	B cells
	metacluster_16.6	4.15	0.181	SOX1; SOX14; SOX15; SOX18; SOX2; SOX2; SOX8; SRY (directAnnotation). SOX1; SOX10; SOX17; SOX3 (inferredBy_Orthology).	B cells
	transfac_pro__M06075	4.04	0.177	ZNF197 (directAnnotation).	B cells
	swissregulon__hs__YY1	3.99	0.175	YY1 (directAnnotation).	B cells
	metacluster_112.1	3.99	0.175	ZNF433 (directAnnotation).	B cells
	taipale_tf_pairs__TEAD4_DLX2_NRCATTCNNNNYAATTN_CAP_repr	3.86	0.171	DLX2; TEAD4 (directAnnotation).	B cells
	transfac_pro__M06543	3.8	0.169	ZNF418 (directAnnotation).	B cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
JUN	tfdimers__MD00036	up	B cells	pre
FOXP1	metacluster_134.4	down	B cells	pre
CREM	transfac_pro__M00801	down	CD8+ T cells	pre
FOSL2	metacluster_157.2	down	cDCs	pre
FOSL2	transfac_pro__M03870	down	cDCs	pre
FOSL2	metacluster_137.2	down	cDCs	pre
HSF1	transfac_pro__M04761	down	Erythrocytes	pre
HMGA1	tfdimers__MD00410	down	Erythrocytes	pre
KLF10	metacluster_170.2	up	Malignant cells	pre
KLF2	metacluster_170.2	up	Malignant cells	pre

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."